Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia, Dysphonia, Injection site erythema, Injection site pain, Injection site pruritus
Clinical narrative: runny nose-clear drainage; nasal congestion; Hair loss; Injection site rash; Injection site itching; Injection site pain; Pain in extremity; Injection site redness; Injection site urticaria; Joint range of motion decreased; Voice disturbance; Squamous cell carcinoma; peripheral neuropathy; Sore throat; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of SQUAMOUS CELL CARCINOMA (Squamous cell carcinoma) and NEUROPATHY PERIPHERAL (peripheral neuropathy) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Squamous cell carcinoma and Rheumatoid arthritis since an unknown date. Concomitant products included CELECOXIB (CELEBREX), HYDROCHLOROTHIAZIDE;LISINOPRIL, TRAMADOL HCL, METHOTREXATE, VITAMIN D3, PYRIDOXINE HYDROCHLORIDE (VITAMIN B-6) and CYANOCOBALAMIN (VITAMIN B-12).    On 30-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Apr-2021, the patient experienced SQUAMOUS CELL CARCINOMA (Squamous cell carcinoma) (seriousness criterion medically significant), NEUROPATHY PERIPHERAL (peripheral neuropathy) (seriousness criterion medically significant), OROPHARYNGEAL PAIN (Sore throat), INJECTION SITE RASH (Injection site rash), INJECTION SITE PRURITUS (Injection site itching), INJECTION SITE PAIN (Injection site pain), PAIN IN EXTREMITY (Pain in extremity), INJECTION SITE ERYTHEMA (Injection site redness), INJECTION SITE URTICARIA (Injection site urticaria), JOINT RANGE OF MOTION DECREASED (Joint range of motion decreased) and DYSPHONIA (Voice disturbance). On an unknown date, the patient experienced RHINORRHOEA (runny nose-clear drainage), NASAL CONGESTION (nasal congestion) and ALOPECIA (Hair loss). The patient was treated with ADALIMUMAB (HUMIRA) (subcutaneous) at a dose of 40 mg every two weeks. At the time of the report, SQUAMOUS CELL CARCINOMA (Squamous cell carcinoma), NEUROPATHY PERIPHERAL (peripheral neuropathy), INJECTION SITE PRURITUS (Injection site itching), INJECTION SITE PAIN (Injection site pain), PAIN IN EXTREMITY (Pain in extremity), INJECTION SITE ERYTHEMA (Injection site redness), INJECTION SITE URTICARIA (Injection site urticaria), JOINT RANGE OF MOTION DECREASED (Joint range of motion decreased) and DYSPHONIA (Voice disturbance) outcome was unknown, OROPHARYNGEAL PAIN (Sore throat), RHINORRHOEA (runny nose-clear drainage), NASAL CONGESTION (nasal congestion) and ALOPECIA (Hair loss) was resolving and INJECTION SITE RASH (Injection site rash) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient was treated with CLARITIN, BIOTON and TYLENOL COLD & SINUS after receiving MODERNA vaccine.  Very limited information regarding the events has been provided at this time.  Further information has been requested.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 13-May-2021: Added Patient medical history, concomitants and events.; Sender's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.